Immune checkpoint inhibitors, including the antibodies that block CTLA-4 (cytotoxic T-lymphocyte-associated protein-4) and PD-1 (programmed cell death protein-1) expressed on lymphocyte membranes, aim to enhance T-cell infiltration in melanoma and stimulate an immune response against the tumor [24]. The gene discussed is PDCD1; the disease is melanoma.